Aberdeen Group plc Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Aberdeen Group plc reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,309 shares of the medical equipment provider’s stock after selling 6,740 shares during the quarter. Aberdeen Group plc owned approximately 0.08% of Zimmer Biomet worth $15,044,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Uncommon Cents Investing LLC grew its position in shares of Zimmer Biomet by 19.2% in the 4th quarter. Uncommon Cents Investing LLC now owns 24,948 shares of the medical equipment provider’s stock worth $2,243,000 after buying an additional 4,020 shares during the period. Lodestone Wealth Management LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at about $82,000. Mn Services Vermogensbeheer B.V. grew its position in Zimmer Biomet by 0.9% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 76,244 shares of the medical equipment provider’s stock valued at $6,856,000 after purchasing an additional 644 shares during the last quarter. Eastern Bank grew its position in Zimmer Biomet by 4.5% during the 4th quarter. Eastern Bank now owns 3,740 shares of the medical equipment provider’s stock valued at $336,000 after purchasing an additional 160 shares during the last quarter. Finally, Dakota Wealth Management grew its position in Zimmer Biomet by 12.8% during the 4th quarter. Dakota Wealth Management now owns 11,831 shares of the medical equipment provider’s stock valued at $1,064,000 after purchasing an additional 1,342 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Price Performance

NYSE ZBH opened at $90.99 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $108.51. The company’s 50 day moving average is $92.40 and its two-hundred day moving average is $93.55. The stock has a market cap of $17.61 billion, a price-to-earnings ratio of 25.70, a PEG ratio of 1.86 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same period last year, the firm posted $2.31 EPS. The company’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings downgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 23rd. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. Finally, Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.